Similarly, cagrilintide, a novel amylin analog, has proven its safety and efficacy at reducing weight and improving metabolic outcomes in patients with overweight or obesity [175,176,177,178,179], and has a number of studies in phase III (Table 1). This evidence concerns the gene IAPP and obesity disorder.